Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: Evidence from the CitAD study

American Journal of Psychiatry

Volumn 173, Issue 5, 2016, Pages 473-480

  Leonpacher, Anne K ^{a,b,c,d,e,f,g,h,i}   Peters, Matthew E ^{a,b,c,d,e,f,g,h,i}   Drye, Lea T ^{a,b,c,d,e,f,g,h,i}   Makino, Kelly M ^{a,b,c,d,e,f,g,h,i}   Newell, Jeffery A ^{a,b,c,d,e,f,g,h,i}   Devanand, D P ^{a,b,c,d,e,f,g,h,i}   Frangakis, Constantine ^{a,b,c,d,e,f,g,h,i}   Munro, Cynthia A ^{a,b,c,d,e,f,g,h,i}   Mintzer, Jacobo E ^{a,b,c,d,e,f,g,h,i}   Pollock, Bruce G ^{a,b,c,d,e,f,g,h,i}   Rosenberg, Paul B ^{a,b,c,d,e,f,g,h,i}   Schneider, Lon S ^{a,b,c,d,e,f,g,h,i}   Shade, David M ^{a,b,c,d,e,f,g,h,i}   Weintraub, Daniel ^{a,b,c,d,e,f,g,h,i}   Yesavage, Jerome ^{a,b,c,d,e,f,g,h,i}   Lyketsos, Constantine G ^{a,b,c,d,e,f,g,h,i}   Porsteinsson, Anton P ^{a,b,c,d,e,f,g,h,i}  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f Roper St Francis Healthcare   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; PLACEBO; ANTIDEPRESSANT AGENT;

AGITATION; ALZHEIMER DISEASE; ANXIETY; ARTICLE; CONTROLLED STUDY; DELUSION; DEPRESSION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHORIA; EATING DISORDER; EUPHORIA; HALLUCINATION; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MENTAL DISEASE; MENTAL INSTABILITY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP DISORDER; TREATMENT RESPONSE; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DELUSIONS; DRUG EFFECTS; FEMALE; HALLUCINATIONS; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; CITALOPRAM; DELUSIONS; FEMALE; HALLUCINATIONS; HUMANS; IRRITABLE MOOD; MALE; SLEEP WAKE DISORDERS;

EID: 84965156027     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2016.15020248     Document Type: Article

References (38)

1. Hebert LE, Weuve J, Scherr PA, et al: Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013; 80:1778-1783
2. Lyketsos CG, Lopez O, Jones B, et al: Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA 2002; 288:1475-1483
3. Steinberg M, Corcoran C, Tschanz JT, et al: Risk factors for neuropsychiatric symptoms in dementia: The Cache County Study. Int J Geriatr Psychiatry 2006; 21:824-830
4. Allegri RF, Sarasola D, Serrano CM, et al: Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer's disease. Neuropsychiatr Dis Treat 2006; 2:105-110
5. Rabins PV, Schwartz S, Black BS, et al: Predictors of progression to severe Alzheimer's disease in an incidence sample. Alzheimers Dement 2013; 9:204-207
6. American Geriatrics Society; American Association for Geriatric Psychiatry: Consensus statement on improving the quality of mental health care in US nursing homes: Management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 2003; 51:1287-1298
7. Molinari V, Chiriboga D, Branch LG, et al: Provision of psychopharmacological services in nursing homes. J GerontolB Psychol Sci Soc Sci 2010; 65B:57-60
8. Alexopoulos GS, Streim J, Carpenter D, et al: Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65(suppl 2):5-99
9. Jeste DV, Blazer D, Casey D, et al: ACNP White Paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008; 33:957-970
10. Cohen-Mansfield J, Jensen B: Assessment and treatment approaches for behavioral disturbances associatedwith dementia in the nursing home: Self-reports of physicians' practices. JAmMed Dir Assoc 2008; 9:406-413
11. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:191-210
12. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934-1943
13. Schneider LS, Tariot PN, Dagerman KS, et al: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355:1525-1538
14. BallardCG, Gauthier S,CummingsJL, et al:Managementof agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009; 5:245-255
15. Geda YE, Schneider LS, Gitlin LN, et al: Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. Alzheimers Dement 2013; 9:602-608
16. Coupland C, Dhiman P, Morriss R, et al: Antidepressant use and risk of adverse outcomes in older people: Population based cohort study. BMJ 2011; 343:d4551
17. Nyth AL, Gottfries CG: The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: A Nordic multicentre study. Br J Psychiatry 1990; 157:894-901
18. Schneider LS, Sobin PB: Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementia. Psychopharmacol Bull 1992; 28:71-79
19. Drye LT, Ismail Z, Porsteinsson AP, et al: Citalopram for agitation in Alzheimer's disease: Design and methods. Alzheimers Dement 2012; 8:121-130
20. Porsteinsson AP, Drye LT, Pollock BG, et al: Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA 2014; 311:682-691
21. Levin HS, High WM, Goethe KE, et al: The Neurobehavioural Rating Scale: Assessment of the behavioural sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry 1987; 50: 182-193
22. Schneider LS, Olin JT, Doody RS, et al: Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S22-S32
23. Cohen-Mansfield J: Conceptualization of agitation: Results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Int Psychogeriatr 1996; 8(suppl 3): 309-315
24. Cummings JL: The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 1997; 48(suppl 6): S10-S16
25. Galasko D, Bennett D, Sano M, et al: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S33-S39
26. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
27. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
28. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314
29. Lyketsos CG, Steinberg M: Behavioral measures for cognitive disorders, in Handbook of Psychiatric Measures. Washington, DC, American Psychiatric Association, 2000, pp 393-416
30. Peters ME, Rosenberg PB, Steinberg M, et al: Neuropsychiatric symptoms as risk factors for progression fromCINDto dementia: The Cache County Study. Am J Geriatr Psychiatry 2013; 21:1116-1124
31. Delucchi KL, Bostrom A: Methods for analysis of skewed data distributions in psychiatric clinical studies: Working with many zero values. Am J Psychiatry 2004; 161:1159-1168
32. Rubin DB: Multiple imputation after 18+ years. JAmStat Assoc 1996; 91:473-489
33. Siddique H, Hynan LS, Weiner MF: Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. J Clin Psychiatry 2009; 70:915-918
34. Sweet RA, Pollock BG, Sukonick DL, et al: The 5-HTTPR polymorphismconfers liability to a combinedphenotype of psychoticand aggressive behavior in Alzheimer disease. Int Psychogeriatr 2001; 13: 401-409
35. Pollock BG, Mulsant BH, Rosen J, et al: Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159:460-465
36. Pollock BG, MulsantBH,RosenJ, et al:Adouble-blindcomparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007; 15:942-952
37. CummingsJ, Isaacson S, Mills R, et al:Pimavanserin for patientswith Parkinson's disease psychosis: A randomised, placebo-controlled phase 3 trial. Lancet 2014; 383:533-540
38. Drye LT, Spragg D, Devanand DP, et al: Changes in QTc interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) randomized trial. PLoS One 2014; 9:e98426